BREAKING: Futures Climb With Tesla Deliveries, September Payrolls On Tap Genmab (GMAB), on Monday, announced its plan to buy cancer-focused biotech company Merus (MRUS) for about $8 billion. The news sent Merus stock into the stratosphere. Merus is working on a drug called petosemtamab, which can simultaneously block two drivers of cancer. Its most advanced program is in head-and-neck cancer, but Merus is also testing the drug in patients with metastatic colorectal cancer. Petosemtamab could generate$3 bi ...